| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,740,000 |
| Market
Cap: |
69.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.28 - $21.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients with rare infectious diseases. Co.'s initial product candidate, epetraborole, an antibiotic under development as a once-daily, oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,787,778 |
1,894,632 |
| Total Buy Value |
$0 |
$0 |
$16,053,772 |
$16,898,592 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
9 |
| Total Shares Sold |
0 |
321,491 |
565,631 |
657,255 |
| Total Sell Value |
$0 |
$6,268,666 |
$10,233,675 |
$11,689,612 |
| Total People Sold |
0 |
6 |
6 |
6 |
| Total Sell Transactions |
0 |
12 |
36 |
50 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aziz Kabeer |
|
– • • |
2023-09-29 |
4 |
AS |
$16.28 |
$1,613,364 |
I/I |
(99,101) |
394,639 |
|
24% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-28 |
4 |
AS |
$16.11 |
$21,845 |
I/I |
(1,356) |
410,403 |
|
25% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-28 |
4 |
AS |
$16.11 |
$115,348 |
D/D |
(7,160) |
2,169,680 |
|
25% |
|
| Aziz Kabeer |
|
– • • |
2023-09-28 |
4 |
AS |
$16.11 |
$137,193 |
I/I |
(8,516) |
410,403 |
|
25% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-27 |
4 |
AS |
$16.07 |
$2,153 |
I/I |
(134) |
411,759 |
|
26% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-27 |
4 |
AS |
$16.07 |
$11,361 |
D/D |
(707) |
2,176,840 |
|
26% |
|
| Aziz Kabeer |
|
– • • |
2023-09-27 |
4 |
AS |
$16.07 |
$13,515 |
I/I |
(841) |
411,759 |
|
26% |
|
| Aziz Kabeer |
|
– • • |
2023-09-13 |
4 |
AS |
$16.00 |
$6,400 |
I/I |
(400) |
411,893 |
|
26% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-13 |
4 |
AS |
$16.00 |
$1,024 |
I/I |
(64) |
411,893 |
|
26% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-13 |
4 |
AS |
$16.00 |
$5,376 |
D/D |
(336) |
2,177,547 |
|
26% |
|
| Aziz Kabeer |
|
– • • |
2023-09-07 |
4 |
AS |
$16.05 |
$54,217 |
I/I |
(3,378) |
411,957 |
|
34% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-07 |
4 |
AS |
$16.05 |
$8,619 |
I/I |
(537) |
411,957 |
|
34% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-07 |
4 |
AS |
$16.05 |
$45,598 |
D/D |
(2,841) |
2,177,883 |
|
34% |
|
| Aziz Kabeer |
|
– • • |
2023-09-06 |
4 |
AS |
$16.02 |
$60,267 |
I/I |
(3,762) |
412,494 |
|
27% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-06 |
4 |
AS |
$16.02 |
$9,580 |
I/I |
(598) |
412,494 |
|
27% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-09-06 |
4 |
AS |
$16.02 |
$50,687 |
D/D |
(3,164) |
2,180,724 |
|
27% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-08-23 |
4 |
S |
$16.00 |
$1,024 |
I/I |
(64) |
413,092 |
|
-32% |
|
| Adjuvant Capital Management, Llc |
|
– – • |
2023-08-23 |
4 |
S |
$16.00 |
$5,376 |
D/D |
(336) |
2,183,888 |
|
-32% |
|
| Aziz Kabeer |
|
– • • |
2023-08-23 |
4 |
S |
$16.00 |
$6,400 |
I/I |
(400) |
413,092 |
|
-32% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2023-08-18 |
4 |
B |
$9.00 |
$16,000,002 |
I/I |
1,777,778 |
5,135,683 |
1.5 |
88% |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2023-05-15 |
4 |
B |
$5.38 |
$53,770 |
I/I |
10,000 |
1,015,766 |
2.66 |
151% |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2022-11-14 |
4 |
AS |
$15.04 |
$346 |
D/D |
(23) |
4,907 |
|
-36% |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2022-11-10 |
4 |
AS |
$15.32 |
$67,628 |
D/D |
(4,413) |
4,930 |
|
-29% |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2022-11-09 |
4 |
AS |
$15.61 |
$157,847 |
D/D |
(10,111) |
4,907 |
|
-32% |
|
| Easom Eric |
Chief Executive Officer |
• • – |
2022-11-08 |
4 |
AS |
$15.41 |
$109,947 |
D/D |
(7,055) |
15,018 |
|
-36% |
|
88 Records found
|
|
Page 2 of 4 |
|
|
0.07 (2.89%) 
